RAINBOW
Made ramucirumab plus paclitaxel the standard second-line stomach cancer treatment, a role it held for a decade until Enhertu and Claudin drugs arrived.
OS 9.6 vs 7.4 months (HR 0.81; Lancet Oncology 2014). With REGARD (ramucirumab alone), established VEGFR2 blockade in gastric cancer. Remains the second-line standard for HER2-negative disease and the comparator in DESTINY-Gastric04 and CLARITY-Gastric01.
Setting
Second-line advanced gastric/GEJ cancer: ramucirumab + paclitaxel vs paclitaxel
Phase
Phase 3
Sponsor
Eli Lilly
Registry
Headline result
OS 9.6 vs 7.4 months, HR 0.81.
Reported
2014
Enrolled
665
Replication
Consistent with REGARD (monotherapy OS benefit) and RAINBOW-Asia.
In plain words
What these results mean for people, not percentages
Overall survivalprimarysurvival endpoint
- Median 9.6 vs 7.4 months with Ramucirumab + paclitaxel compared with Placebo + paclitaxel; about 2.2 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 19 percent lower chance of the event at any given time (hazard ratio 0.81).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Second-line advanced gastric/GEJ cancer: ramucirumab + paclitaxel vs paclitaxel. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
665 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Ramucirumab + paclitaxel | 330 | 9.6 months | 0.81 | — | link |
| Placebo + paclitaxel | 335 | 7.4 months |
Replication
Consistent with REGARD (monotherapy OS benefit) and RAINBOW-Asia.